Join Katalin Kelemen, MD, PhD and Ruben A. Mesa, MD from Mayo Clinic Cancer Center as they present their expertise on a range of cases pertaining to myeloproliferative neoplasms, with a specific focus on myelofibrosis.
Myelofibrosis (MF) is one of the BCR-ABL1-negative myeloproliferative neoplasms (MPN). This group also includes polycythemia vera (PV) and essential thrombocythemia (ET). MPNs are associated with a risk of transformation to acute myeloid leukemia, and the incidence is more frequent in patients with MF. The selection of treatment is based on the risk score and the presence of symptoms.
NCCN is offering a series of twelve multidisciplinary case-based webinars on a variety of topics, bladder cancer, breast cancer, colorectal cancer, kidney cancer, lung cancer, melanoma, multiple myeloma, myelofibrosis, ovarian cancer, peripheral T-cell lymphomas, prostate cancer and sarcoma. Each webinar will be facilitated by at least two faculty members. A different topic will be presented each month for twelve months (June 2016 until June 2017). The goal of this Series is to ensure that members of a multidisciplinary team, including physicians, nurses, pharmacists and other relevant healthcare professionals, have the knowledge and skills necessary to apply the standards of care to their practice and healthcare setting for patients with various cancer types.
The NCCN Clinical Practice Guidelines in Oncology® (NCCN Guidelines®) are a set of step-by step evidence-based, consensus-driven recommendations that ensure that patients receive preventive, diagnostic treatment, and care that is most likely to lead to optimal outcomes. The NCCN recommendations are applicable to about 95% of patients. Clinicians need to consider the current clinical status of the patient, including general health, disease specifics, concomitant conditions, current and previous therapies, and the patients how to best apply appropriate standard of care including identifying circumstances where appropriate management requires adapting the NCCN Guidelines to the needs of the individual. This activity series will discuss the specific recommendations in the NCCN Guidelines as well as unique patient circumstances that impact how the NCCN Guidelines might be best applied.
Tuesday, December 13, 2016 9:15 AM - 10:15 AMEastern Time
NCCN Meetings Department
World Time Zone MapSee when meeting occurs in other time zonesWorld Time Zone Map
NCCN.org – For Clinicians | NCCN.org/patients – For Patients
National Comprehensive Cancer Network | 275 Commerce Drive | Suite 300 | Fort Washington | PA | 19034 | US | 215.690.0300